Deals, pipeline readouts and company news from across biotech and pharma.
The US company says net sales of its NPM1-mutated AML therapy rose 53%, and it has agreed a registrational design with the FDA for darlifarnib in HRAS-mutant salivary gland cancer.
The US dermatology company's third-quarter results show first revenue from an online cosmetic product, $5.0 million in cash and a new acne trial ahead of a planned 2027 launch.
The life-sciences tools supplier posted 5% revenue growth and a $158M net loss after a $149M impairment, and forecast FY2027 revenue of $648-660M.
The maker of the Freedom subcutaneous infusion system posted a small profit, improved its gross margin and trimmed its full-year revenue range while lowering its margin outlook.
The deal brings ZYNRELEF, APONVIE, CINVANTI and SUSTOL under CorMedix, with about $150 million in trailing-12-month net revenue and a Pharmakon term loan backing the purchase.
The cell-engineering company reported $10.2 million in third-quarter revenue and plans to buy a GMP-grade reagent supplier, partly funded by a $22 million credit facility draw.
Atossa Therapeutics reported lower third-quarter operating expenses and created a contingent value right linked to any sale of a priority review voucher it has yet to receive.
The company cites stronger XIAFLEX growth and Acthar Gel performance, and plans an FDA filing for XIAFLEX in plantar fibromatosis early next year.
Arbutus reported $59.1M net income for Q3 2026, as it and Genevant widened LNP patent litigation in Japan and Canada and the FDA cleared its oral PD-L1 candidate.
The oncology biotech kept its Q1 2027 target for top-line OPERA-01 data, appointed a new CFO and plans an OP-3136 prostate cancer study in Q4 2026.
The company's Q3 2026 update also confirms a $205M priority review voucher sale and the start of dosing in a Phase 2 facioscapulohumeral muscular dystrophy study.
Net product sales rose 31% quarter on quarter, yet a $389.7M charge for the October settlement with United Therapeutics drove a GAAP net loss.
Protalix BioTherapeutics reported nine-month revenue of $75.6M and net income of $26.1M, while enrolment continues in its Phase 2 PRX-115 gout study.
The Israeli plasma-derived therapeutics company cites U.S. KEDRAB sales as the main driver of $152.2 million in nine-month revenue and now expects 2026 revenue of $205-208 million.
Jiade Limited's unaudited half-year accounts show revenue slipping to RMB 8.3m while general and administrative spending climbed to RMB 48.8m, including about RMB 33m of share-based pay.
Kamada's unaudited interim accounts to 30 September 2026 show higher revenue and profit year on year, lower R&D spending and $24.2M in declared dividends.
The Israeli biotech's Yavne CDMO operations and an expanded U.S. customer deal drove sales growth, but a one-off accounting gain masks a wider operating loss.
The US maker of pharmaceuticals, cosmetic ingredients and medical lubricants reported Q3 2026 net income of $930,912, with Renacidin the main driver of pharmaceutical growth.
A four-year exclusive deal with minimum purchase commitments covers Israel, with revenue expected from 2027 and talks on HMO reimbursement to follow.
The Eversense 365 maker reported Q3 revenue of $19.6M, driven by US growth, and raised its full-year outlook to $68-70M.
The US genomic testing company kept its full-year revenue range, cut volume and revenue growth expectations, and raised its adjusted gross margin target to about 71%.
The portable MRI maker narrowed its quarterly loss to $6.0 million, kept 2026 revenue guidance and flagged an FDA submission for its Contrast PMR study by year-end.
The US sterilisation-assurance supplier issued its first fiscal 2027 guidance and said a September FDA inspection of its Montana biological indicator site closed without Form 483 observations.
The US ophthalmic company held its full-year sales guidance, lowered its profit outlook to above $40 million, and brought forward its planned G-MELT NDA submission to 2026.
The company now expects 2026 revenue of $337–351 million and adjusted EBITDA of $176–190 million, citing the Jazz milestone, the Theravance acquisition and the Roche ZW209 licence.
The medical device maker reported third-quarter net sales of $207.9M and an adjusted EBITDA of $26.0M, while U.S. spine sales fell 4.3%.
CorMedix will acquire substantially all of Heron's assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, for cash, shares and contingent earn-outs, with closing expected in Q1 2027.
CorMedix has agreed to buy substantially all of Heron's assets, including four hospital-use products for postoperative pain and nausea and vomiting, with closing expected in the first quarter of 2027.
The US company reported $35.1M in third-quarter revenue, a net profit of $7.0M and $104.3M in cash with no debt, and said HEPZATO is now at 33 active centres.
The Simoa maker reported third-quarter revenue ahead of expectations and set out neurology assay launches, a 2027 IVD submission plan for HD-X and updated 2026 guidance.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.